MetaCap

ProKidney (PROK) vs Tevogen (TVGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ProKidney (PROK) has outperformed Tevogen (TVGN) over the past year, losing 52.5% versus a loss of 73.8%. ProKidney is the larger company by market cap ($415.2 million vs $405.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PROK-52.51%TVGN-73.84%
+22%-33%-88%
Nov 21, 20251 yearNov 20, 2026
PROK-89.48%TVGN-98.81%
+37%-34%-106%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PROK versus TVGN key metrics
MetricPROKTVGN
Share price$1.04$5.90
Market cap$415.21M$405.20M
1-day change-1.89%-6.35%
YTD return-53.57%-64.35%
1-year return-52.51%-73.84%
5-year return-89.49%—
EPS (TTM)$-0.61$-7.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$893.00K—
Revenue growth (YoY)+1075.00%—
Net income (latest FY)$-68.99M$-26.28M
Operating margin-18477.83%—
Net margin-7725.20%—
52-week high$2.65$24.90
52-week low$0.87$3.64
Distance from 52-week high-60.75%-76.31%
Analyst consensusbuy—
Avg. price target upside+525.00%—
Average volume1.44M7.94K
Shares outstanding209.63M68.68M
Employees23118
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PROK has outperformed TVGN by 21.3 percentage points over the past year.

About ProKidney

PROK stock →

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees

About Tevogen

TVGN stock →

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

PROK vs TVGN FAQ

Which is bigger, ProKidney or Tevogen?

ProKidney (PROK) is larger, with a market capitalization of $415.21M compared with $405.20M for Tevogen (TVGN).

Which stock has performed better over the past year, PROK or TVGN?

PROK returned -52.51% over the past 12 months, compared with -73.84% for TVGN (price return, excluding dividends). Past performance does not predict future results.

Are ProKidney and Tevogen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons